Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Primary hyperparathyroidism

Primary hyperparathyroidism

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Primary hyperparathyroidism

11 trials tracked for Primary hyperparathyroidism: 7 in phase 3 or 4 and 1 with published results. The most-cited published study has 74 citations.

11Trials tracked
7Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 6 Other / NA 4
  1. Phase 3 Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Completed · 74 cited
  2. Phase 4 Vitamin D Repletion in Primary Hyperparathyroidism Completed
  3. Phase 3 Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Completed
  4. Phase 3 18F-Fluorocholine for the Detection of Parathyroid Adenomas Completed
  5. Phase 3 Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism Completed
  6. Phase 3 Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy Completed
Show 5 more trials
  1. Phase 3 Effect of Vitamin D Treatment in Primary Hyperparathyroidism Completed
  2. N/A Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy Completed
  3. N/A Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy Completed
  4. N/A Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy Completed
  5. N/A PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Primary hyperparathyroidism: what the trials found

Cinacalcet has been shown to significantly reduce plasma parathyroid hormone (PTH) levels during the early assessment period (EAP) 6. Clinical data also indicate that Cinacalcet is associated with significant changes in bone mineral density across multiple sites, including the lumbar spine 2, total hip 2, and femoral neck 2.

Long-term administration of Cinacalcet was evaluated regarding dosage adjustments; studies recorded varying frequencies of dose or frequency changes during the first 3 months, at 3-6 months, and after 6 months post-initiation 11.

Other interventions investigated in primary hyperparathyroidism include Vitamin D3 1, Cholecalciferol 7, eplerenone (which showed no significant change in PTH or calcium levels 3), and KHK7580 5. Additionally, 18F-Fluorocholine was utilized in clinical trials 4.

Recent results — preliminary, needs further review

  • The PTeye imaging technique was evaluated for identifying parathyroid glands; results showed no significant difference in the average number of glands identified (2.7 vs 2.6) or PTH levels 5-14 days post-surgery (23 vs 25.3), but did show a statistically significant difference in the proportion of patients achieving an appropriate intraoperative PTH drop 9.

For the clinician treating this condition

  • Cinacalcet is effective for reducing plasma parathyroid hormone levels and is associated with measurable changes in lumbar spine, total hip, and femoral neck bone mineral density.
  • Eplerenone did not demonstrate a statistically significant effect on PTH or calcium levels in clinical trials.
  • PTeye imaging shows promise in surgical navigation, though it did not significantly change the average number of glands identified compared to standard methods.

AI synthesis of 9 cited trials, updated Jul 31, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Parathyroidectomy and hypercalcemia management may improve outcomes in patients with primary hyperparathyroidism
Anesthesiology & Pain Medicine Sys. Review
Parathyroidectomy and hypercalcemia management may improve outcomes in patients with primary hyperparathyroidism Hyperparathyroidism May Link to Recurrent Pregnancy Loss in Older Mothers
This case report and literature review examines the management of primary hyperparathyroidism in a patient with recurrent pregnancy loss. Th…
A single case report suggests that correcting hypercalcemia and removing a parathyroid gland may help patients with recurrent pregnancy loss…
Frontiers Aug 27, 2026
Concurrent osteosarcoma can be masked by brown tumors in patients with primary hyperparathyroidism
Oncology Sys. Review
Concurrent osteosarcoma can be masked by brown tumors in patients with primary hyperparathyroidism Rare bone cancer hidden by hyperparathyroidism in elderly patient
This case report and literature review describes a 65-year-old female whose hip lesion was initially mistaken for a brown tumor from primary…
A woman with a hip lesion and high parathyroid hormone levels was found to have a rare bone cancer called osteosarcoma.
Frontiers Jul 31, 2026